Home / Health / NHS Blood Test Trial: Can it Save Lives?
NHS Blood Test Trial: Can it Save Lives?
26 Nov
Summary
- Multi-cancer detection tests identify cancerous DNA fragments in blood.
- NHS trial involves over 140,000 volunteers testing the Galleri blood test.
- Concerns exist about false positives and missed cancers in current availability.
The NHS is participating in the world's largest trial of multi-cancer detection (MCD) tests, specifically the Galleri test developed by US firm Grail. These innovative tests aim to identify cancer early by detecting circulating DNA fragments shed from tumors, often pinpointing the cancer's origin. Over 140,000 volunteers have joined this significant trial, with results anticipated next year, potentially influencing future NHS diagnostic pathways.
While the Galleri test holds promise for early detection, its effectiveness and life-saving potential are under scrutiny. Reports from the United States, where the test is publicly available, indicate instances where it missed some cancers. Furthermore, a significant number of individuals received positive results only to be later found not to have the disease, a phenomenon known as a false positive.
As hospitals grapple with missed cancer treatment targets, the NHS is exploring advanced diagnostic tools like MCD tests. This trial's outcomes will be crucial in determining if such blood tests can be a reliable and life-saving addition to early cancer diagnosis efforts, balancing the promise of early detection against the risks of inaccurate results.
